Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuang, Chung-Fengen_US
dc.contributor.authorYu, Ming-Lungen_US
dc.date.accessioned2020-02-02T23:54:37Z-
dc.date.available2020-02-02T23:54:37Z-
dc.date.issued2019-06-01en_US
dc.identifier.issn2287-2728en_US
dc.identifier.urihttp://dx.doi.org/10.3350/cmh.2018.1014en_US
dc.identifier.urihttp://hdl.handle.net/11536/153576-
dc.description.abstractDuring the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have always been excluded. Apart from the clinical trials, more HCC patients are currently being treated in daily practice, given that these treatments are highly effective and involve well-tolerated regimens. Large scale, real-world studies have demonstrated potentially suboptimal antiviral treatment efficacy in HCC patients who received DAAs. It is postulated that the impairment of the bioavailability of DAAs may account for the inferior treatment response. However, the results could not be generalized across all studies. The differing results were attributed to diverse patient characteristics, suboptimal regimens or imprecise definitions of active cancer statuses at the time of treatment initiation. Additional large-scale studies that utilize the treatment of choice in clearly defined HCC patients with different disease severities are warranted to clarify the issue.en_US
dc.language.isoen_USen_US
dc.subjectHepatocellular carcinoma (HCC)en_US
dc.subjectChronic hepatitis C (CHC)en_US
dc.subjectHepatitis C virus (HCV)en_US
dc.titleDirect-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?en_US
dc.typeArticleen_US
dc.identifier.doi10.3350/cmh.2018.1014en_US
dc.identifier.journalCLINICAL AND MOLECULAR HEPATOLOGYen_US
dc.citation.volume25en_US
dc.citation.issue2en_US
dc.citation.spage168en_US
dc.citation.epage171en_US
dc.contributor.department生物科技學院zh_TW
dc.contributor.department生醫工程研究所zh_TW
dc.contributor.departmentCollege of Biological Science and Technologyen_US
dc.contributor.departmentInstitute of Biomedical Engineeringen_US
dc.identifier.wosnumberWOS:000472600100003en_US
dc.citation.woscount0en_US
Appears in Collections:Articles